Immunological Relevance of the Coevolution of IDO1 and AHR by Jaronen, Merja & Quintana, Francisco J.
 
Immunological Relevance of the Coevolution of IDO1 and AHR
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Jaronen, Merja, and Francisco J. Quintana. 2014.
“Immunological Relevance of the Coevolution of IDO1 and
AHR.” Frontiers in Immunology 5 (1): 521.
doi:10.3389/fimmu.2014.00521.
http://dx.doi.org/10.3389/fimmu.2014.00521.
Published Version doi:10.3389/fimmu.2014.00521
Accessed February 17, 2015 6:45:50 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13454826
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MINI REVIEW ARTICLE
published: 20 October 2014
doi: 10.3389/ﬁmmu.2014.00521
Immunological relevance of the coevolution of IDO1 and
AHR
Merja Jaronen and Francisco J. Quintana*
Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Edited by:
Ursula Grohmann, University of
Perugia, Italy
Reviewed by:
Ursula Grohmann, University of
Perugia, Italy
Francesca Fallarino, University of
Perugia, Italy
Michael Platten, German Cancer
Research Center, Germany
*Correspondence:
Francisco J. Quintana, Center for
Neurologic Diseases, Brigham and
Women’s Hospital, Harvard Medical
School, Boston, MA 02115, USA
e-mail: fquintana@rics.bwh.
harvard.edu
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor initially iden-
tiﬁed because of its role in controlling the cellular response to environmental molecules.
More recently, AHR has been shown to play a crucial role in controlling innate and adaptive
immune responses through several mechanisms, one of which is the regulation of tryp-
tophan metabolism. Indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase
(TDO)areconsideredrate-limitingenzymesinthetryptophancatabolismandplayimportant
roles in the regulation of the immunity. Moreover, AHR and IDO/TDO are closely intercon-
nected: AHR regulates IDO and TDO expression, and kynurenine produced by IDO/TDO
is an AHR agonist. In this review, we propose to examine the relationship between AHR
and IDO/TDO and its relevance for the regulation of the immune response in health and
disease.
Keywords: aryl hydrocarbon receptor, 2,3-dioxygenase, tryptophan-2,3-dioxygenase
AHR SIGNALING PATHWAYS
Aryl hydrocarbon receptor belongs to the family of basic-helix–
loop–helix/Per–Arnt–Sim transcription factors. It is abundantly
expressed in numerous tissues, such as liver, lung, and placenta
(1, 2). Interestingly, AHR is highly conserved through evolution
(3),highlighting its importance across the animal kingdom. Orig-
inally,AHRwasstudiedinthecontextof thebiologicalresponseto
environmentaltoxinssuchas2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD). However, it was later found that AHR has an important
role in the regulation of immune responses by small molecules
provided by the diet, the commensal ﬂora, and metabolism. In
its inactive state, AHR resides in the cytosol as part of a complex
that includes other proteins such as the 90kDa heat shock protein
(HSP90),theAHR-interactingprotein,p23,andthec-SRCprotein
kinase(4–7).ItisthoughtthatHSP90andp23protectthereceptor
from proteolysis and maintain a conformation suitable for ligand
binding (8).
Aryl hydrocarbon receptor is activated by ligands binding the
PAS-Bdomain(9),triggeringaconformationalchangethatresults
in the dissociation of AHR from the chaperone proteins and the
exposure of its nuclear localization sequence (10). Ligand activa-
tion of AHR elicits genomic and non-genomic AHR-dependent
signaling pathways. Genomic AHR signaling involves the inter-
action of AHR with other transcription factors and co-activators
to directly regulate the transcription of target genes (7). After lig-
andactivation,AHRtranslocatestothenucleuswhereitdimerizes
with theAHR nuclear translocator (ARNT) (11) to form an active
DNA-binding complex and control the expression of target genes
containing xenobiotic response elements (XREs) in their regula-
toryregions(9).TheAHR–ARNTcomplexcanpromoteorinhibit
theexpressionofitstargetgenes.Moreover,ChIP-seqandmicroar-
ray studies with different cell types and ligands (12–14) suggest
that the AHR target genes in a speciﬁc cell are determined by the
ligands,andalsotheidentityanddevelopmentalstageof thetarget
cells (15).
Non-genomicAHRsignalingismorediverseandencompasses,
for example, the release of c-SRC from its complex with AHR,
resulting in the phosphorylation of c-SRC cellular targets (7). In
addition,AHRcanpromotethedegradationof speciﬁctargetpro-
teins such as estrogen and androgen receptors by the proteasome.
This ability to trigger the degradation of speciﬁc proteins results
from its E3 ligase activity,by whichAHR selects proteins for ubiq-
uitination by E2 ubiquitin-conjugating enzymes. The resulting
ubiquitinated proteins are then recognized by the 26S proteasome
and degraded (16–18). Indeed, following activation AHR itself is
eventuallyexportedoutfromthenucleusanddegradedbythe26S
proteasome pathway (19–21).
Structure–activity relationship studies showed that AHR’s lig-
and binding pocket is promiscuous and able to accommodate
numerous hydrophobic planar compounds (22). From an his-
toric point of view, AHR can be seen as an endocrine-disrupting
chemicals (EDCs) receptor, as it is known that EDCs affect the
endocrine system either directly by AHR-dependent changes in
gene expression or indirectly via AHR cross-talk with endocrine
signaling pathways (23). However, both endogenous and exoge-
nous AHR ligands have been identiﬁed. Classical AHR ligands
include synthetic aromatic and polycyclic aromatic hydrocar-
bons (HAHs and PAHs) as well as natural ligands tetrapyrroles,
ﬂavonoids, tryptophan derivatives, and dietary carotinoids (24).
Interestingly, some of the natural AHR ligands, such as resvera-
trol (25) and 7-ketocholestrol (26) can act as antagonists rather
than agonists. Within the endogenous AHR ligands, tryptophan-
derived metabolites have become one of the most interesting and
utmost studied group (7). It should be noted that AHR activation
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intheabsenceof ligandbindinghasalsobeendescribed.Although
the relevance of this observation for vertebrates is not completely
understood,theligand-independentactivationofAHRmightplay
a physiological role in invertebrates (see below).
AHR EVOLUTION
Arylhydrocarbonreceptorhomologshavebeenidentiﬁedinmost
major groups of animals,including the two main clades of proto-
stome invertebrates as well as deuterostomes (27,28) highlighting
the biological importance of AHR throughout the animal king-
dom. AHR homologs identiﬁed in invertebrates share similarities
with their vertebrate counterparts, such as the interaction with
ARNT to recognize XRE (29–31). However, invertebrate AHR
homologs do not bind known AHR ligands like TCDD or b-
naphthoﬂavone (29, 31). Indeed, it was recently reported that the
metabolic response to xenobiotics in Caenorhabditis elegans is not
controlled by AHR (32).
In C. elegans, the orthologs of AHR and ARNT are encoded
by the AHR-related (ahr-1) and ahr-1 associated (aha-1) genes,
respectively. AHR-1 and AHA have HSP90 binding properties
comparabletothoseof theirmammaliancounterparts(31).AHR-
1 shares 38% amino acid identity with the human AHR over
the ﬁrst 395 amino acids. Furthermore, AHR-1 contains a PAS
domain with both PAS-A and PAS-B repeats as well as a bHLH
domain where speciﬁc residues mediating the recognition of
mammalian XREs are conserved (31). However, AHR-1 does not
have a glutamine-rich transcriptional activation domain similar
to the one present in mammals.
Notably,mutations inAHR-1 affect several aspects of neuronal
development determining, for example, the fate of GABAergic
neuronsintheL1larvalstage,regulatingbothcellandaxonmigra-
tions as well as specifying the fate of AVM light touch sensory
neuron (33–35). In addition, AHR-1 is involved in social feed-
ing (36), in which nematodes form groups on the border of the
bacterial lawn (37).
Recent studies have also demonstrated a role forAHR-1 in reg-
ulating the synthesis of long-chain unsaturated fatty acids that
eventually produce lipid signaling molecules (38). This ﬁnding is
consistentwithﬁndingsinmousemodels,whereligandactivation
of AHR has been linked to alterations in gene expression of fatty
acid metabolism (39, 40).
The homologs of mammalian AHR and ARNT are encoded
by spineless and tango in Drosophila melanogaster (41, 42). In
agreement with observations made in C. elegans, spineless does
not bind TCDD or b-naphthoﬂavone (29). In addition, sequence
alignments suggest that key residues required for the interaction
of mammalian AHR with TCDD are not conserved in spineless
(29, 41). Thus, although it is still possible that the localization
and/or the activity of spineless are modiﬁed by unknown endoge-
nous ligands, it appears that this protein does not bind classical
AHR ligands functional in mammalian systems. Moreover,in cer-
taincellsspinelessappearstobeconstitutivelyactive(43).Spineless
plays a role in several aspects of antenna and leg development (41,
44),photoreceptor cell differentiation (45),and in controlling the
morphology of sensory neurons (46).
Not surprisingly, most of our knowledge on mammalian AHR
comes from studies on human beings and mice. Key features
characterizing mammalian AHR are (1) in contrast to other ver-
tebrates (47) all studied mammalians have a single AHR gene
and (2) AHR in mammals is not only involved in the toxic
effects of environmental pollutants (48, 49), it also has important
roles in development (50–53) and immune responses [reviewed
in Ref. (7)]. Indeed, it has been hypothesized that the original
function of the AHR might have been developmental regulation
and that AHR’s ability to bind HAHs, PAHs, and mediate adap-
tive responses involving induction of xenobiotic-metabolizing
enzymes is a vertebrate innovation (3, 47).
KYNURENINE PATHWAYS TDO/IDO AND IMMUNE
REGULATION
Tryptophan metabolites have become one of the most interest-
inggroupsof endogenousAHRligands.Especiallykynurenine,an
immediate tryptophan metabolite,has been extensively studied in
recent years. The metabolic fate of tryptophan is conversion into
a range of neuroactive substances, such as serotonin and mela-
tonin.Inaddition,tryptophancanbecatabolizedintokynurenine
metabolites. Indoleamine-2,3-dioxygenase (IDO1), tryptophan-
2,3-dioxygenase (TDO), and recently discovered IDO-related
enzyme IDO2 (54) are the ﬁrst and rate-limiting enzymes con-
verting tryptophan to N-formylkynurenine (55,56) which is then
metabolized to l-kynurenine. Both TDO and IDO1 are thought
to be intracellular enzymes (57, 58). Therefore, ATP-binding cas-
sette (ABC) transporter (59), enzyme facilitating cellular entry
of tryptophan, is considered to be another rate-limiting factor in
tryptophan catabolism (60). l-Kynurenine can be catabolized by
three different ways: (1) kynurenine monooxygenase, kynuren-
inase, and 3-hydroxyanthranilic acid oxidase catalyze the syn-
thesis of anthranilic acid, 3-hydroxyanthranilic acid, quinolinic
acid, and 3-hydroxykynurenine. (2) Kynurenine aminotransfer-
eases catalyze the synthesis of kynurenic acid. (3) Kynurenine
monooxygenase and kynurenine aminotransfereases catalyze the
synthesis of xanthurenic acid (Figure 1) [reviewed in Ref. (61)].
In human beings, IDO1 is expressed in various tissues and cell
subsets following cytokine stimulation during infection, trans-
plantation, pregnancy, autoimmunity, and neoplasia (62–64).
IDO1 is constitutively expressed in many human tumors,creating
an immunosuppressive microenvironment as a result of trypto-
phan depletion and the synthesis of immunosuppressive metabo-
lites such as kynurenine (65, 66). Surprisingly, the expression of
IDO1iscontrolledbyAHR(67)viaanautocrineAHR-IL6-STAT3
signaling loop (68). In addition, tryptophan starvation caused by
IDO1activity,togetherwithIDO1-dependenttryptophancatabo-
lism,inhibitstheproliferationandactivationof antigen-speciﬁcT
lymphocytes and induces immune tolerance (69–72). In addition,
strong evidence suggests that tryptophan catabolism can inhibit
T-cell based adaptive immunity by inducing the differentiation
of regulatory T cells (Treg) in tumors (62, 73–75). Interestingly,
kynurenineisalsoindicatedtopromotethedifferentiationofTregs
(76) while suppressing antigen-speciﬁc T-cell responses (77).
In mammals,TDO2 is expressed primarily in the liver (78–80)
but can also be detected in other tissues such as the brain (79,81–
83). TDO2 is constitutively expressed and activated in gliomas
(84). Recently, lipopolysaccharide was demonstrated to induce
TDO2 expression and via consequent production of kynurenine
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FIGURE 1 | Interplay between tryptophan metabolism andAHR.
Tryptophan is metabolized byTDO2 and IDO1 to L-kynurenine, which is further
converted to kynurenic acid. Both L-kynurenine and kynurenic acid can
activate AHR. In addition, AHR activity is inﬂuenced by environment and
therapy. Finally, AHR can activate either genomic or non-genomic
AHR-dependent signaling pathways. Red arrows indicate tryptophan
catabolism pathways, blue arrows indicate AHR activation, and black arrows
indicate pathways activated by AHR.
activate AHR-dependent pathways leading to protection against
endotoxin challenge (85). In addition, this study also reported
thatendotoxintoleranceisalsomediatedbyAHRasitwasdemon-
stratedthatAHRactivationbykynurenineelicitsthec-SRCdepen-
dent phosphorylation of IDO1, which further regulates TGFb1
production by dendritic cells as well as limits immunopathology
triggered by both Salmonella typhimurium and group B Strep-
tococcus (85). Furthermore, TDO2 derived kynurenine has been
demonstrated to suppress antitumor immune responses as well
as promote survival and motility of tumor cells via AHR in an
autocrine manner (84). Note that kynurenic acid can also activate
AHR signaling (86).
IDO/TDO EVOLUTION
Unfortunately, not much is know about the kynurenine pathway
in nematodes. However, the study of intestinal autoﬂuorescence
in relation to tryptophan catabolism revealed that nematodes
having a mutated ﬂu-1 gene show altered gut granule autoﬂuo-
resence as well as decreased kynurenine hydroxylase activity (87).
Whereas,ﬂu-2 mutants have reduced kynureninase and gut gran-
ule autoﬂuorescence (87). In support of these observations, the
C. elegans genome has homologs of kynurenine hydroxylase and
kynureninase in the vicinity of ﬂu-1 and ﬂu-2 loci (88).
Additional putative kynurenine pathway related genes have
been identiﬁed in the C. elegans genome (89) (Figure 2). The
knock down of tdo-2, for example, abrogated the gut granule
ﬂuorescence (90, 91). Involvement of the C. elegans kynurenine
pathway has been demonstrated in neurodegeneration and aging:
in a C. elegans model of Parkinson’s disease; RNAi knock down
of tdo-2 reduced a-synuclein aggregation-induced toxicity and
Tryptophan
N-formylkynurenine
Human
IDO
Kynurenine
3-hydroxy-
kynurenine
3-hydroxy-
anthranillic acid
kmo-1 / KMO / cinnabar
ﬂu-2 / KYNU / ?
Kyneric acid
Xanthurenic
acid
KATII/
KATIII/
KATI
Anthranillic
acid
C.elegans D.melanogaster
tdo-2 / TDO / vermillion
afmid-1 /AFMID / CG9542
nkat-
1/nkat-
3/tatn-1
CG6950
cardinal
ﬂu-2 / KYNU / ?
Ommochromosomes
FIGURE 2 | Schematic representation of the kynurenine pathway in
human beings (mammal), C. elegans, and D. melanogaster. Pathway tree
demonstrates differences between mammalian and invertebrate tryptophan
catabolism. Mammalian enzymes are depicted in black, C. elegans enzymes
in blue, and D. melanogaster in red. Modiﬁed from Ref. (89)
increased life span (92). However, these effects were proven to
be a result of increased tryptophan rather than changed levels of
kynurenines (92).
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In D. melanogaster, tryptophan catabolism takes place in pig-
mentedeyes(93–95).Remarkably,theroleof kynureninepathway
in eye function is conserved from ﬂies to mammals, as it plays
an essential role in protecting the lens from ultraviolet irradia-
tion (96). D. melanogaster TDO2 is encoded by vermillion. Flies
having the vermillion mutation lack brown pigment in their eyes
and have been thought to be deﬁcient for TDO2 activity (93, 94,
97, 98). This was veriﬁed when kynurenine pathway and related
genes were described in full in 2003 (99). In the same way,as in C.
elegans, loss of vermillion function has been demonstrated to be
neuroprotectiveinD.melanogaster modelof Huntington’sdisease
(100). In addition, loss of vermillion function extend the life span
of D. melanogaster (101, 102) while resulting gradual memory
decline (103). Furthermore, white eye mutants having impaired
ABC transport show extended life spans (102). In addition, other
D.melanogaster mutants,cardinalandcinnabar,resultinginexcess
of 3-hydroxykynurenineandneuroprotectivekynurenicacid,have
been demonstrated to modify the brain plasticity (104).
CONCLUSION
Aryl hydrocarbon receptor, a member of the dHLH-PAS super-
family, has been identiﬁed both in invertebrates and vertebrates,
suggesting that the ancestral AHR gene arose over 500 million
years ago (3). In vertebrates, especially in mammals, the activ-
ity of AHR is mostly regulated by its interactions with ligands.
However, in invertebrates (e.g. C. elegans) AHR does not seem to
interact with TCDD or any other known ligand (105), and it is
constitutively localized in the nuclei of certain cells suggesting
ligand-independent activation (34). Similar observations have
beenmadeforD.melanogaster´sspineless (29).Althoughonecan-
not rule out the possibility that invertebrates require a different
kind of AHR ligands than vertebrates, it has been speculated that
in early metazoans AHR might have had a ligand-independent
rolesindevelopment.Thus,theabilityofAHRtointeractwithlig-
ands,bindHAHsandPAHs,andregulatexenobiotic-metabolizing
enzymes has been postulated to be a vertebrate novelty (3, 47).
Aryl hydrocarbon receptor signaling modulates development
andimmunefunctioninmammals(7).Fairlyrecently,theinvolve-
mentof tryptophanmetabolismhasbeenimplicatedinregulating
both innate and adaptive immune responses. Most importantly,
kynurenine produced by TDO or IDO1 during tryptophan catab-
olism has been identiﬁed as an AHR ligand, linking IDO/TDO to
AHR. Considering the evolutionary conservation of the kynure-
ninepathway,itistemptingtospeculatethatthecross-talkbetween
AHR and IDO/TDO immunoregulatory pathways is a recent evo-
lutionaryinnovationaimedatprovidingamechanismtoﬁnetune
theimmuneresponseinresponsetoenvironmentalcuesprovided
by the tissue microenvironment. This interpretation suggests that
approaches targeting both AHR and IDO/TDO are likely to pro-
vide efﬁcient new avenues for the therapeutic manipulation of the
immune response.
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